1932

Abstract

We review the recent literature on financing biomedical innovation, with a specific focus on the drug development process and how it may be enhanced to improve outcomes. We begin by laying out stylized facts about the structure of the drug development process and its associated costs and risks, and we present evidence that the rate of discovery for life-saving treatments has declined over time while costs have increased. We make the argument that these structural features require drug development (i.e., biopharmaceutical) firms to rely on external financing and at the same time amplify market frictions that may hinder the ability of these firms to obtain financing, especially for treatments that may have large societal value relative to the benefits going to the firms and their investors. We then provide an overview of the evidence for various types of market frictions to which these drug development firms are exposed and discuss how these frictions affect their incentive to invest in the development of new drugs, leading to underinvestment in valuable treatments. In light of this evidence, numerous studies have proposed ways to overcome this funding gap, including the use of financial innovation. We discuss the potential of these approaches to improve outcomes.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-financial-031721-081537
2022-11-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/financial/14/1/annurev-financial-031721-081537.html?itemId=/content/journals/10.1146/annurev-financial-031721-081537&mimeType=html&fmt=ahah

Literature Cited

  1. Adelino M, Lewellen K, McCartney WB. 2022. Hospital financial health and clinical choices: evidence from the financial crisis. Manag. Sci. 68:32098–119
    [Google Scholar]
  2. Adelino M, Lewellen K, Sundaram A. 2015. Investment decisions of nonprofit firms: evidence from hospitals. J. Finance 70:41583–628
    [Google Scholar]
  3. Aghamolla C, Karaca-Mandic P, Li X, Thakor RT. 2021. Merchants of death: the effect of credit supply shocks on hospital outcomes NBER Work. Pap. 28709
  4. Aghamolla C, Thakor RT. 2022a. Do mandatory disclosure requirements for private firms increase the propensity of going public?. J. Account. Res. 60:3755–804
    [Google Scholar]
  5. Aghamolla C, Thakor RT. 2022b. IPO peer effects. J. Financ. Econ. 144:1206–26
    [Google Scholar]
  6. Aghion P, Bloom N, Blundell R, Griffith R, Howitt P. 2005. Competition and innovation: an inverted-U relationship. Q. J. Econ. 120:2701–28
    [Google Scholar]
  7. Alvarez DL, Lo AW. 2022. Differentiated dollars: venture philanthropy investment. Nat. Biotechnol. 40:458–62
    [Google Scholar]
  8. Angus DC, Alexander BM, Berry S, Buxton M, Lewis R et al. 2019. Adaptive platform trials: definition, design, conduct and reporting considerations. Nat. Rev. Drug Discov. 18:10797–807
    [Google Scholar]
  9. Ball GP, Shah R, Wowak KD. 2018. Product competition, managerial discretion, and manufacturing recalls in the US pharmaceutical industry. J. Oper. Manag. 58:59–72
    [Google Scholar]
  10. Benmelech E, Eberly J, Papanikolaou D, Krieger J. 2021. Private and social returns to R&D: drug development and demographics. AEA Pap. Proc. 111:336–40
    [Google Scholar]
  11. Bernstein S. 2015. Does going public affect innovation?. J. Finance 70:41365–403
    [Google Scholar]
  12. Berry D, Berry S, Hale P, Isakov L, Lo AW et al. 2020. A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidates. PLOS ONE 15:12e0244418 https://doi.org/10.1371/journal.pone.0244418
    [Crossref] [Google Scholar]
  13. Besanko D, Thakor AV. 1987a. Collateral and rationing: sorting equilibria in monopolistic and competitive credit markets. Int. Econ. Rev. 28:3671–89
    [Google Scholar]
  14. Besanko D, Thakor AV. 1987b. Competitive equilibrium in the credit market under asymmetric information. J. Econ. Theory 42:1167–82
    [Google Scholar]
  15. Bhattacharya S, Chiesa G. 1995. Proprietary information, financial intermediation, and research incentives. J. Financ. Intermed. 4:4328–57
    [Google Scholar]
  16. Bhattacharya S, Ritter JR. 1983. Innovation and communication: signalling with partial disclosure. Rev. Econ. Stud. 50:2331–46
    [Google Scholar]
  17. Boot AWA, Thakor AV. 1993. Security design. J. Finance 48:41349–78
    [Google Scholar]
  18. Boot AWA, Vladimirov V. 2019. ‘Collusion’ with public and private ownership and innovation. SSRN Work. Pap. 3057555
    [Google Scholar]
  19. Branstetter L, Chatterjee C, Higgins MJ. 2014. Starving (or fattening) the golden goose?. Generic entry and the incentives for early-stage pharmaceutical innovation NBER Work. Pap. 20532
    [Google Scholar]
  20. Branstetter L, Chatterjee C, Higgins MJ. 2016. Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry. RAND J. Econ. 47:4857–90
    [Google Scholar]
  21. Brown JR, Fazzari SM, Petersen BC. 2009. Financing innovation and growth: cash flow, external equity, and the 1990s R&D boom. J. Finance 64:1151–85
    [Google Scholar]
  22. Budish E, Roin BN, Williams H. 2015. Do firms underinvest in long-term research? Evidence from cancer clinical trials. Am. Econ. Rev. 105:72044–85
    [Google Scholar]
  23. Burnham TC, Huang S, Lo AW. 2017. Pricing for survival in the biopharma industry: a case study of Acthar Gel and Questcor Pharmaceuticals. J. Invest. Manag. 15:469–91
    [Google Scholar]
  24. Carlson R. 2016. Estimating the biotech sector's contribution to the US economy. Nat. Biotechnol. 34:3247–55
    [Google Scholar]
  25. Caves RE, Whinston MD, Hurwitz MA. 1991. Patent expiration, entry, and competition in the U.S. pharmaceutical industry. Brookings Pap. Econ. Activ. Microecon. 22:1–66
    [Google Scholar]
  26. Centers for Medicare and Medicaid Services (CMS) 2021. Historical national health expenditure data. CMS Washington, DC: Updated Dec. 15. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsHistorical
  27. Chaudhuri SE, Cheng K, Lo AW, Pepke S, Rinaudo S et al. 2019. A portfolio approach to accelerate therapeutic innovation in ovarian cancer. J. Invest. Manag. 17:25–16
    [Google Scholar]
  28. Chaudhuri SE, Hauber B, Mange B, Zhou M, Ho M et al. 2022. Use of Bayesian decision analysis to maximize value in patient-centered randomized clinical trials in Parkinson's disease Work. Pap. MIT Lab. Financial Eng. Cambridge, MA:
  29. Chaudhuri SE, Ho MP, Irony T, Sheldon M, Lo AW. 2018. Patient-centered clinical trials. Drug Discov. Today 23:2395–401
    [Google Scholar]
  30. Chaudhuri SE, Lo AW. 2020. Financially adaptive clinical trials via option pricing analysis. J. Econom. In press
    [Google Scholar]
  31. Chaudhuri SE, Lo AW 2021a. Bayesian adaptive patient-centered clinical trials Work. Pap. Mass. Inst. Technol., Lab. Financial Eng. Cambridge, MA:
  32. Chaudhuri SE, Lo AW. 2021b. Incorporating patient preferences via Bayesian decision analysis. Clin. J. Am. Soc. Nephrol. 16:1639–41
    [Google Scholar]
  33. Chaudhuri S, Lo AW, Xiao D, Xu Q 2020. Bayesian adaptive clinical trials for anti-infective therapeutics during epidemic outbreaks. Harv. Data Sci. Rev. Spec. Issue 1. https://doi.org/10.1162/99608f92.7656c213
    [Crossref] [Google Scholar]
  34. Cockburn I, Lerner J. 2006. The cost of capital for early-stage biotechnology ventures Work. Pap. Boston Univ. Boston:
  35. Cummings J, Hu A, Su A, Lo AW 2022. Financing Alzheimer's disease drug development. Alzheimer's Disease Drug Development: Research and Development Ecosystem J Cummings, J Kinney, H Fillit 465–79 Cambridge, UK: Cambridge Univ. Press
    [Google Scholar]
  36. Cunningham C, Ederer F, Ma S 2021. Killer acquisitions. J. Political Econ. 129:3649–702
    [Google Scholar]
  37. Dambra M, Field LC, Gustafson MT. 2015. The JOBS Act and IPO volume: evidence that disclosure costs affect the IPO decision. J. Financ. Econ. 116:1121–43
    [Google Scholar]
  38. Danzon PM, Chao L-W. 2000. Does regulation drive out competition in pharmaceutical markets?. J. Law Econ. 43:2311–58
    [Google Scholar]
  39. Danzon PM, Epstein A, Nicholson S. 2007. Mergers and acquisitions in the pharmaceutical and biotech industries. Manag. Decis. Econ. 28:4–5307–28
    [Google Scholar]
  40. Das S, Huang S, Lo AW. 2019. Acceleration of rare disease therapeutic development: a case study of AGIL-AADC. Drug Discov. Today 24:3678–84
    [Google Scholar]
  41. Das S, Lo AW. 2017. Re-inventing drug development: a case study of the I-SPY 2 breast cancer clinical trials program. Contemp. Clin. Trials 62:168–74
    [Google Scholar]
  42. Das S, Rousseau R, Adamson PC, Lo AW. 2018. New business models to accelerate innovation in pediatric oncology therapeutics: a review. JAMA Oncol 4:91274–80
    [Google Scholar]
  43. DeMarzo P, Duffie D 1999. A liquidity-based model of security design. Econometrica 67:165–99
    [Google Scholar]
  44. Deshpande N, Nagendra A. 2017. Patents as collateral for securitization. Nat. Biotechnol. 35:6514–16
    [Google Scholar]
  45. Di Stefano G, Gambardella A, Verona G. 2012. Technology push and demand pull perspectives in innovation studies: current findings and future research directions. Res. Policy 41:81283–95
    [Google Scholar]
  46. DiMasi JA, Feldman L, Seckler A, Wilson A. 2010. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 87:3272–77
    [Google Scholar]
  47. DiMasi JA, Grabowski HG. 2007. The cost of biopharmaceutical R&D: Is biotech different?. Manag. Decis. Econ. 28:4–5469–79
    [Google Scholar]
  48. DiMasi JA, Grabowski HG, Hansen RW. 2016. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47:20–33
    [Google Scholar]
  49. DiMasi JA, Hansen RW, Grabowski HG. 2003. The price of innovation: new estimates of drug development costs. J. Health Econ. 22:2151–85
    [Google Scholar]
  50. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. 1991. Cost of innovation in the pharmaceutical industry. J. Health Econ. 10:2107–42
    [Google Scholar]
  51. DiMasi JA, Hermann JC, Twyman K, Kondru RK, Stergiopoulos S et al. 2015. A tool for predicting regulatory approval after phase II testing of new oncology compounds. Clin. Pharmacol. Ther. 98:5506–13
    [Google Scholar]
  52. Duggan M, Garthwaite C, Goyal A. 2016. The market impacts of pharmaceutical product patents in developing countries: evidence from India. Am. Econ. Rev. 106:199–135
    [Google Scholar]
  53. Eisenberg RS. 2001. The shifting functional balance of patents and drug regulation. Health Aff. 20:5119–35
    [Google Scholar]
  54. El-Maraghi RH, Eisenhauer EA. 2008. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. J. Clin. Oncol. 26:81346–54
    [Google Scholar]
  55. Fagnan DE, Fernandez J-M, Lo AW, Stein RM. 2013. Can financial engineering cure cancer?. Am. Econ. Rev. 103:3406–11
    [Google Scholar]
  56. Fagnan DE, Gromatzky AA, Stein RM, Fernandez J-M, Lo AW. 2014. Financing drug discovery for orphan diseases. Drug Discov. Today 19:5533–38
    [Google Scholar]
  57. Fagnan DE, Yang NN, McKew JC, Lo AW. 2015. Financing translation: analysis of the NCATS rare-diseases portfolio. Sci. Transl. Med. 7:276276ps3
    [Google Scholar]
  58. Fernandez JM, Stein RM, Lo AW. 2012. Commercializing biomedical research through securitization techniques. Nat. Biotechnol. 30:964–75
    [Google Scholar]
  59. Ferreira D, Manso G, Silva AC. 2014. Incentives to innovate and the decision to go public or private. Rev. Financ. Stud. 27:1256–300
    [Google Scholar]
  60. Forman SM, Lo AW, Shilling M, Sweeney GK. 2015. Funding translational medicine via public markets: the business development company. J. Invest. Manag. 13:49–32
    [Google Scholar]
  61. Freilich J. 2019. Prophetic patents. UC Davis Law Rev. 53:663
    [Google Scholar]
  62. Gaessler F, Wagner S. 2022. Patents, data exclusivity, and the development of new drugs. Rev. Econ. Stat. 104:31–16
    [Google Scholar]
  63. Gans JS, Stern S. 2003. The product market and the market for “ideas”: commercialization strategies for technology entrepreneurs. Res. Policy 32:2333–50
    [Google Scholar]
  64. Garfinkel JA, Hammoudeh M. 2022. Competition and innovation revisited: a project-level view SSRN Work. Pap. 3684095
  65. Garthwaite C. 2018. The economics of drug development: pricing and innovation in a changing market. NBER Report. 3:19–24
    [Google Scholar]
  66. Gertner R, Gibbons R, Scharfstein D. 1988. Simultaneous signaling to the capital and product markets. RAND J. Econ. 19:2173–90
    [Google Scholar]
  67. Giambona E, Golec J, Lopez-de-Silanes F. 2021. Do firms purposefully change capital structure? Evidence from an investment-opportunity shock to drug firms. J. Financ. Quant. Anal. 56:3915–44
    [Google Scholar]
  68. Goffin J, Baral S, Tu D, Nomikos D, Seymour L. 2005. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. Clin. Cancer Res. 11:165928–34
    [Google Scholar]
  69. Gogineni K, Shuman KL, Emanuel EJ. 2013. Survey of oncologists about shortages of cancer drugs. N. Engl. J. Med. 369:2463–64
    [Google Scholar]
  70. Grabowski H. 2002. Patents, innovation and access to new pharmaceuticals. J. Int. Econ. Law 5:4849–60
    [Google Scholar]
  71. Grabowski HG, Kyle M. 2007. Generic competition and market exclusivity periods in pharmaceuticals. Manag. Decis. Econ. 28:4–5491–502
    [Google Scholar]
  72. Grabowski HG, Kyle M 2012. Mergers, acquisitions, and alliances. The Oxford Handbook of the Economics of the Biopharmaceutical Industry PM Danzon, S Nicholson 552–78 Oxford, UK: Oxford Univ. Press
    [Google Scholar]
  73. Grabowski H, Vernon J. 1986. Longer patents for lower imitation barriers: the 1984 Drug Act. Am. Econ. Rev. 76:2195–98
    [Google Scholar]
  74. Grabowski H, Vernon J. 1990. A new look at the returns and risks to pharmaceutical R&D. Manag. Sci. 36:7804–21
    [Google Scholar]
  75. Grabowski HG, Vernon JM. 1992. Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act. J. Law Econ. 35:2331–50
    [Google Scholar]
  76. Gruber J. 2022. Financing health care delivery. Annu. Rev. Financ. Econ. 14:209–29
    [Google Scholar]
  77. Guedj I, Scharfstein D. 2004. Organizational scope and investment: evidence from the drug development strategies and performance of biopharmaceutical firms NBER Work. Pap. 10933
  78. Gupta A, Howell ST, Yannelis C, Gupta A. 2021. Does private equity investment in healthcare benefit patients? Evidence from nursing homes NBER Work. Pap. 28474
  79. Hall BH, Lerner J 2010. The financing of R&D and innovation. Handbook of the Economics of Innovation, Vol. 1 ed. BH Hall, N Rosenberg 609–39 Amsterdam: North-Holland
    [Google Scholar]
  80. Haninger K, Jessup A, Koehler K. 2011. ASPE issue brief: economic analysis of the causes of drug shortages Rep. Assist. Secr. Plan. Eval., US Dep. Health Hum. Serv. Washington, DC:
  81. Harrington SE 2012. Cost of capital for pharmaceutical, biotechnology, and medical device firms. The Oxford Handbook of the Economics of the Biopharmaceutical Industry PM Danzon, S Nicholson 75–99 Oxford, UK: Oxford Univ. Press
    [Google Scholar]
  82. Hauber B, Mange B, Zhou M, Chaudhuri S, Benz HL et al. 2021. Parkinson's patients’ tolerance for risk and willingness to wait for potential benefits of novel neurostimulation devices: a patient-centered threshold technique study. MDM Policy Pract. 6:11–13
    [Google Scholar]
  83. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. 2014. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32:40–51
    [Google Scholar]
  84. Henderson R, Cockburn I. 1996. Scale, scope, and spillovers: the determinants of research productivity in drug discovery. RAND J. Econ. 27:132–59
    [Google Scholar]
  85. Hermosilla M. 2021. Rushed innovation: evidence from drug licensing. Manag. Sci. 67:1257–78
    [Google Scholar]
  86. Hermosilla M, Wu Y. 2018. Market size and innovation: the intermediary role of technology licensing. Res. Policy 47:5980–91
    [Google Scholar]
  87. Higgins MJ. 2007. The allocation of control rights in pharmaceutical alliances. J. Corp. Finance 13:158–75
    [Google Scholar]
  88. Higgins MJ, Rodriguez D. 2006. The outsourcing of R&D through acquisitions in the pharmaceutical industry. J. Financ. Econ. 80:2351–83
    [Google Scholar]
  89. Hoberg G, Phillips G. 2010. Product market synergies and competition in mergers and acquisitions: a text-based analysis. Rev. Financ. Stud. 23:103773–811
    [Google Scholar]
  90. Hoberg G, Phillips G. 2016. Text-based network industries and endogenous product differentiation. J. Political Econ. 124:51423–65
    [Google Scholar]
  91. Hsu P-H, Lee K, Moon SK, Oh S. 2019. Information transparency in drug development: evidence from mandatory disclosure of clinical trials SSRN Work. Pap. 3459511
  92. Huang S, Siah KW, Vasileva D, Chen S, Nelsen L, Lo AW 2021. Life sciences intellectual property licensing at the Massachusetts Institute of Technology. Nat. Biotechnol. 39:293–301
    [Google Scholar]
  93. Hull J, Lo AW, Stein RM. 2019. Funding long shots. J. Invest. Manag. 17:49–41
    [Google Scholar]
  94. Isakov L, Lo AW, Montazerhodjat V. 2019. Is the FDA too conservative or too aggressive? A Bayesian decision analysis of clinical trial design. J. Econom. 211:1117–36
    [Google Scholar]
  95. Jardim DL, Groves ES, Breitfeld PP, Kurzrock R. 2017. Factors associated with failure of oncology drugs in late-stage clinical development: a systematic review. . Cancer Treat. Rev. 52:12–21
    [Google Scholar]
  96. Jensen MC. 1986. Agency costs of free cash flow, corporate finance, and takeovers. Am. Econ. Rev. 76:2323–29
    [Google Scholar]
  97. Jørring A, Lo AW, Philipson TJ, Singh M, Thakor RT. 2021. Sharing R&D risk in healthcare via FDA hedges. Rev. Corp. Finance Stud. In press. https://doi.org/10.1093/rcfs/cfab024
    [Crossref] [Google Scholar]
  98. Kamien MI, Schwartz NL. 1978. Potential rivalry, monopoly profits and the pace of inventive activity. Rev. Econ. Stud. 45:3547–57
    [Google Scholar]
  99. Kaplan SN, Strömberg PE. 2004. Characteristics, contracts, and actions: evidence from venture capitalist analyses. J. Finance 59:52177–210
    [Google Scholar]
  100. Kerr WR, Nanda R. 2015. Financing innovation. Annu. Rev. Financ. Econ. 7:445–62
    [Google Scholar]
  101. Kim ES, Lo AW. 2016. Business models to cure rare disease: a case study of Solid Biosciences. J. Invest. Manag. 14:487–101
    [Google Scholar]
  102. Kim ES, Lo AW. 2019. Venture philanthropy: a case study of the Cystic Fibrosis Foundation. SSRN Work. Pap. 3376673
    [Google Scholar]
  103. Kim ES, Omura PMC, Lo AW. 2017. Accelerating biomedical innovation: a case study of the SPARK Program at Stanford University, School of Medicine. Drug Discov. Today 22:1064–68
    [Google Scholar]
  104. Kortum S, Lerner J. 2000. Assessing the contribution of venture capital to innovation. RAND J. Econ. 31:4674–92
    [Google Scholar]
  105. Kremer M, Williams H. 2010. Incentivizing innovation: Adding to the tool kit. Innov. Policy Econ. 10:11–17
    [Google Scholar]
  106. Krieger JL. 2021. Trials and terminations: learning from competitors’ R&D failures. Manag. Sci. 67:95525–48
    [Google Scholar]
  107. Krieger J, Li D, Papanikolaou D. 2022. Missing novelty in drug development. Rev. Financ. Stud. 35:2636–79
    [Google Scholar]
  108. Krieger JL, Li X, Thakor RT. 2022. Find and replace: R&D investment following the erosion of existing products. Manag. Sci. In press. http://doi.org/10.1287/mnsc.2021.4243
    [Crossref] [Google Scholar]
  109. Kyle MK. 2007. Pharmaceutical price controls and entry strategies. Rev. Econ. Stat. 89:188–99
    [Google Scholar]
  110. Kyle MK. 2018. Are important innovations rewarded? Evidence from pharmaceutical markets. Rev. Ind. Organ. 53:1211–34
    [Google Scholar]
  111. Kyle MK. 2020. The alignment of innovation policy and social welfare: evidence from pharmaceuticals. Innov. Policy Econ. 20:195–123
    [Google Scholar]
  112. Lakdawalla DN. 2018. Economics of the pharmaceutical industry. J. Econ. Lit. 56:2397–449
    [Google Scholar]
  113. Lerner J, Shane H, Tsai A. 2003. Do equity financing cycles matter? Evidence from biotechnology alliances. J. Financ. Econ. 67:3411–46
    [Google Scholar]
  114. Lewis CM, White JT. 2020. Deregulating innovation capital: the effects of the JOBS Act on biotech startups SSRN Work. Pap. 3640852
  115. Li X, Liu T, Taylor LA. 2021. Common ownership and innovation efficiency SSRN Work. Pap. 3479439
  116. Li X, Lo AW, Thakor RT. 2021. Paying off the competition: market power and innovation incentives NBER Work. Pap. 28964
  117. Lo AW. 2017. Discussion: new directions for the FDA in the 21st century. Biostatistics 18:3404–7
    [Google Scholar]
  118. Lo AW. 2019. Bayesian decision analysis for randomized clinical trials Lecture in the Healthcare Finance course for the Mass. Inst. Technol. Cambridge, MA: https://bit.ly/3POaKPy
  119. Lo AW, Chaudhuri SE. 2023. Healthcare Finance: Modern Financial Analysis for Accelerating Biomedical Innovation Princeton, NJ: Princeton Univ. Press
  120. Lo AW, Ho C, Cummings J, Kosik KS. 2014. Parallel discovery of Alzheimer's therapeutics. Sci. Transl. Med. 6:241241cm5
    [Google Scholar]
  121. Lo AW, Naraharisetti SV. 2014. New financing methods in the biopharma industry: a case study of Royalty Pharma, Inc. J. Invest. Manag. 12:14–19
    [Google Scholar]
  122. Lo AW, Philipson TJ, von Eschenbach AC. 2016. Health, wealth, and the 21st Century Cures Act. JAMA Oncol. 2:117–18
    [Google Scholar]
  123. Lo AW, Pisano G. 2016. Lessons from Hollywood: a new approach to funding R&D. Sloan Manag. Rev. 57:247–57
    [Google Scholar]
  124. Lo AW, Siah KW. 2021. Financing correlated drug development projects. J. Struct. Finance 27:117–34 https://doi.org/10.3905/jsf.2020.1.114
    [Crossref] [Google Scholar]
  125. Lo AW, Siah KW, Wong CH. 2019. Machine learning with statistical imputation for predicting drug approval. Harv. Data Sci. Rev. 1.1. https://doi.org/10.1162/99608f92.5c5f0525
    [Crossref] [Google Scholar]
  126. Lo AW, Siah KW, Wong CH. 2020. Estimating probabilities of success of clinical trials for vaccines and other anti-infective therapeutics. Harv. Data Sci. Rev. Spec. Issue 1. https://doi.org/10.1162/99608f92.e0c150e8
    [Crossref] [Google Scholar]
  127. Lo AW, Thakor RT. 2019. Risk and reward in the orphan drug industry. J. Portf. Manag. 45:530–45
    [Google Scholar]
  128. Lo AW, Thakor RT. 2022. Financial intermediation and the funding of biomedical innovation: a review Work. Pap. Mass. Inst. Technol., Lab. Financial Eng. Cambridge, MA: https://carlsonschool.umn.edu/sites/carlsonschool.umn.edu/files/2022-04/JFI%20Review%20Lo%20Thakor%20v5.pdf
  129. Lo AW, Zhang R. 2021. Quantifying the impact of impact investing SSRN Work. Pap. 3944367
  130. Mace C. 2020. The real effects of secondary markets on innovation SSRN Work. Pap. 3348102
  131. Maher DP, Wong CH, Siah KW, Lo AW. 2022. Estimates of probabilities of successful development of pain medications: an analysis of pharmaceutical clinical development programs from 2000 to 2020. Anesthesiology 137:243–51
    [Google Scholar]
  132. Malik L, Mejia A, Parsons H, Ehler B, Mahalingam D et al. 2014. Predicting success in regulatory approval from Phase I results. Cancer Chemother. Pharmacol. 74:51099–1103
    [Google Scholar]
  133. Mann W. 2018. Creditor rights and innovation: evidence from patent collateral. J. Financ. Econ. 130:125–47
    [Google Scholar]
  134. Mishra B, Qi Q, Rudolph L, Savas F, Weill M. 2018. BURPA or Bust! How to Build a Bio-Unified Research Project Agency? Speaker at the 2nd Workshop on Trusted Smart Contracts, Financial Cryptography 2018 Curaçao: Feb. 26–March 2. Abstract available here: https://cs.nyu.edu/∼mishra/PUBLICATIONS/18.BURPA.pdf
  135. Montazerhodjat V, Chaudhuri SE, Sargent DJ, Lo AW. 2017. Use of Bayesian decision analysis to minimize harm in patient-centered randomized clinical trials in oncology. JAMA Oncol. 3:9e170123
    [Google Scholar]
  136. Montazerhodjat V, Frishkopf JJ, Lo AW. 2016. Financing drug discovery via dynamic leverage. Drug Discov. Today 21:3410–14
    [Google Scholar]
  137. Montazerhodjat V, Weinstock DM, Lo AW. 2016. Buying cures versus renting health: financing health care with consumer loans. Sci. Transl. Med. 8:327327ps6
    [Google Scholar]
  138. Myers SC, Howe CD. 1997. A life-cycle financial model of pharmaceutical R&D Program on the Pharmaceutical Industry, Sloan School of Management, Massachusetts Institute of Technology Cambridge, MA:
  139. Myers SC, Majluf NS. 1984. Corporate financing and investment decisions when firms have information that investors do not have. J. Financ. Econ. 13:2187–221
    [Google Scholar]
  140. Phillips GM, Sertsios G. 2017. Financing and new product decisions of private and publicly traded firms. Rev. Financ. Stud. 30:51744–89
    [Google Scholar]
  141. Rampini AA, Viswanathan S. 2013. Collateral and capital structure. J. Financ. Econ. 109:2466–92
    [Google Scholar]
  142. Ringel MS, Scannell JW, Baedeker M, Schulze U. 2020. Breaking Eroom's Law. Nat. Rev. Drug Discov. 19:12833–34
    [Google Scholar]
  143. Scannell JW, Blanckley A, Boldon H, Warrington B. 2012. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11:3191–200
    [Google Scholar]
  144. Sharp P, Jacks T, Hockfield S. 2016. Capitalizing on convergence for health care. Science 352:62931522–23
    [Google Scholar]
  145. Siah KW, Kelley NW, Ballerstedt S, Holzhauer B, Lyu T et al. 2021a. Predicting drug approvals: the Novartis data science and artificial intelligence challenge. Patterns 2:8100312 https://doi.org/10.1016/j.patter.2021.100312
    [Crossref] [Google Scholar]
  146. Siah KW, Khozin S, Wong CH, Lo AW. 2019. Machine-learning and stochastic tumor growth models for predicting outcomes in patients with advanced non-small-cell lung cancer. JCO Clin. Cancer Inform. 3:1–11
    [Google Scholar]
  147. Siah KW, Maher DP, Lo AW 2022. Financing pharmaceuticals and medical devices for pain treatment and opioid use disorder. Emerg. Trends Drugs Addict. Health 2:100045
    [Google Scholar]
  148. Siah KW, Xu Q, Tanner K, Futer O, Frishkopf JJ, Lo AW. 2021b. Accelerating glioblastoma therapeutics via venture philanthropy. Drug Discov. Today 26:71744–49
    [Google Scholar]
  149. Stern AD. 2017. Innovation under regulatory uncertainty: evidence from medical technology. J. Public Econ. 145:181–200
    [Google Scholar]
  150. Thakor RT, Anaya N, Zhang Y, Vilanilam C, Siah KW et al. 2017. Just how good an investment is the biopharmaceutical sector?. Nat. Biotechnol. 35:121149–57
    [Google Scholar]
  151. Thakor RT, Lo AW. 2017. Optimal financing for R&D-intensive firms NBER Work. Pap. 23831
  152. Thakor RT, Lo AW. 2022. Competition and R&D financing: evidence from the biopharmaceutical industry. J. Financ. Quant. Anal. 57:5)1885–928
    [Google Scholar]
  153. Thomas DW, Burns J, Audette J, Carroll A, Dow-Hygelund C, Hay M. 2016. Clinical development success rates 2006–2015 Rep. Biotechnol. Innov. Organ. Washington, DC:
  154. Thomas DW, Chancellor D, Micklus A, LaFever S, Hay M et al. 2021. Clinical development success rates and contributing factors 2011–2020 Rep. Biotechnol. Innov. Organ. Washington, DC:
  155. US Food and Drug Administration (FDA) 2018. The drug development process, step 3: clinical research US FDA Washington, DC: Updated Jan. 4. https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
  156. Vasileva D, Norton L, Hurlbert M, Lo AW. 2022. Measuring the economic and academic impact of philanthropic funding: the Breast Cancer Research Foundation. J. Invest. Manag. 20:15–24
    [Google Scholar]
  157. Vernon JA. 2005. Examining the link between price regulation and pharmaceutical R&D investment. Health Econ. 14:11–16
    [Google Scholar]
  158. Vu JT, Kaplan BK, Chaudhuri SE, Mansoura MK, Lo AW. 2022. Financing vaccines for global health security. J. Invest. Manag. 20:251–67
    [Google Scholar]
  159. Williams HL. 2017. How do patents affect research investments?. Annu. Rev. Econ. 9:441–69
    [Google Scholar]
  160. Wong CH, Li D, Wang N, Gruber J, Conti R, Lo AW. 2021. Estimating the financial impact of gene therapy in the U.S NBER Work. Pap. 28628
  161. Wong CH, Siah KW, Lo AW. 2019a. Estimation of clinical trial success rates and related parameters. Biostatistics 20:2273–86 https://doi.org/10.1093/biostatistics/kxx069
    [Crossref] [Google Scholar]
  162. Wong CH, Siah KW, Lo AW. 2019b. What are the chances of getting a cancer drug approved?. DIA Global Forum May. https://bit.ly/2pUuBWs
    [Google Scholar]
  163. Yang X, Debonneuil E, Zhavoronkov A, Mishra B. 2016. Cancer megafunds with in silico and in vitro validation: accelerating cancer drug discovery via financial engineering without financial crisis. Oncotarget 7:57671–78 https://doi.org/10.18632/oncotarget.9808
    [Crossref] [Google Scholar]
/content/journals/10.1146/annurev-financial-031721-081537
Loading
/content/journals/10.1146/annurev-financial-031721-081537
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error